Bright Peak Therapeutics
brightpeaktx.com
Actively hiring
Cell & Gene Therapy
Biotechnology
Health Care
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Total raised
$90M
1 round on record
Latest round
$90M
Series C · Jun 2024 · 2 yr ago
Backers
1
RA Capital Management
The money's age
Long since its last round
27 months since the last round · not hiring
Momentum
0/100
no fresh signals
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Apr 17, 2025
Board appointment Bright Peak Therapeutics Appoints John Schmid to its Board of Directors · brightpeaktx.com
2012
Founded
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Series C | Jun 2024 | $90M | Johnson lead, 2024 Ba | brightpeaktx.com |
Backed byfrom the funds' portfolios and accelerator catalogs
RA Capital Management Similar startupsby what they do, their industry and backers
Unleashing unconventional antigens for cancer immunotherapy. Learn about our technology.
Cancer immunotherapy that turns cancer cells into biofactories minting their own destruction.
Adventris Pharmaceuticals is a biotechnology company focusing on cancer immunotherapy.
Shinobi Therapeutics is transforming cell therapy with scalable, immune-evasive iPSC-derived treatments for cancer and autoimmune diseases.
Reprogramming is the next leap forward in cancer immunotherapy. Asgard Therapeutics is a Swedish private biotech company exploring direct…
Alia Therapeutics is a startup which is developing next-generation gene editing medicines to cure genetic diseases.
News
Bright Peak Therapeutics Appoints John Schmid to its Board of Directors
April 17, 2025 -San Diego, California and Basel, Switzerland -Bright Peak Therapeutics, a clinical-stage biotechnology company focused on discovering and developing multifunctional immunotherapies for cancer, today announced the appointment of John Schmid
Read more
Report
John Schmid
Mr. Schmid brings more than 35 years of financial and senior management experience in the biotechnology industry. As a Chief Financial Officer, he has raised over $900 million through private and public equity and debt financings. He has guided two compan
Read more
Report
Bright Peak Therapeutics To Participate in 43rd Annual J.P. Morgan Healthcare Conference
January 6, 2025 - Basel, Switzerland and San Diego, California -Bright Peak Therapeutics, a clinical-stage biotechnology company focused on discovering and developing multifunctional immunotherapies for cancer, today announced that Fredrik Wiklund, Chief
Read more
Report
Identification of PD1-IL2(TAP) - a PD-1 Blocking Immunoconjugate Harboring a Tumor-Activatable Masked IL-2 Payload Lacking Binding to IL2Rbeta/CD122
The post Identification of PD1-IL2(TAP) - a PD-1 Blocking Immunoconjugate Harboring a Tumor-Activatable Masked IL-2 Payload Lacking Binding to IL2Rbeta/CD122 appeared first on Bright Peak Therapeutics.
Read more
Report
Bright Peak Therapeutics Presents New Data at the 2024 Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
- BPT958, a bifunctional PD-1 immunoconjugate with a masked IL-2 payload designed to be processed specifically in the tumor microenvironment - -In preclinical models, BPT958 induces potent antitumor activity with minimal systemic activation - November 8,
Read more
Report
Bright Peak Therapeutics Announces Dosing of First Patient in Phase 1/2a Clinical Trial of BPT567, a First-in-Class Bifunctional PD1-IL18 Immunoconjugate
- BPT567 is the first bifunctional PD1-IL18 immunoconjugate to enter clinical development - - Phase 1/2a study will evaluate BPT567 in patients with locally advanced/unresectable or metastatic solid tumors - October 17, 2024 - Basel, Switzerland and San D
Read more
Report
Bright Peak Therapeutics Announces $90 Million in Series C Financing to Advance First-in-Class PD1-IL18 Immunoconjugate Program Into Clinical Trials
- Lead Program, BPT567, will be the first PD1-IL18 immunoconjugate to enter the clinic; Phase 1/2a study in solid tumors expected to begin in 2H 2024 - - Financing led by Johnson & Johnson with participation by new and existing investors- June 11, 2024 Ba
Read more
Report
Bright Peak Therapeutics Presents New Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting
-BPT567, a first-in-class PD1-IL18 immunoconjugate designed to enable cis-signaling and preferentially activate intratumoral PD1+IL18R+ effector T cells induces potent preclinical antitumor activity SAN DIEGO, California & BASEL, Switzerland, April 9 2024
Read more
Report
The first-in-class PD1-IL18 conjugate BPT567 induces potent anti-tumor immunity by preferentially activating PD1+IL18R+ intratumoral effector T cells in cis
The post The first-in-class PD1-IL18 conjugate BPT567 induces potent anti-tumor immunity by preferentially activating PD1+IL18R+ intratumoral effector T cells in cis appeared first on Bright Peak Therapeutics.
Read more
Report
Show more news
Financials
Total raised
$90M
Latest round
Series C
Funding rounds
1
Funding rounds
| Round | Announced | Amount | |
|---|---|---|---|
| Series C | 2024 | $90M | Details |